CLPTM1L and pancreatic neoplasm: Given our previous demonstration of chemosensitization of pancreatic tumor cells to chemotherapeutic killing and inhibition of anchorage independent growth and tumorigenesis using murine monoclonal antibodies (mAbs) targeting CLPTM1L12, we developed fully human antibodies with antagonism for CLPTM1L.